文献速递慢阻肺

L-精氨酸联合脂质体维生素C改善接受肺康复的慢阻肺合并慢性呼吸衰竭患者的疲劳:多中心随机安慰剂对照试验

Targeting fatigue in COPD with chronic respiratory failure undergoing pulmonary rehabilitation: a multicentre, randomised, placebo-controlled trial of L-arginine/liposomal vitamin C.
PubMed 文献 · Thorax · 2026-09-18

这项多中心随机双盲安慰剂对照试验纳入98例稳定期慢阻肺合并慢性呼吸衰竭且接受长期氧疗的患者,在28天标准化肺康复期间口服L-精氨酸联合脂质体维生素C或安慰剂。结果显示干预组疲劳严重程度量表(FSS)下降幅度显著大于安慰剂组,但功能及患者报告次要结局无显著组间差异。

要点

  • 在28天肺康复期间加用L-精氨酸/脂质体维生素C可显著改善慢阻肺合并慢性呼吸衰竭患者的疲劳评分。
  • FSS组间平均差异为-0.90(95%CI -1.50至-0.29;p=0.004),超过预设最小临床重要差异0.6分。
  • 6分钟步行距离、坐立试验、握力、CAT及mMRC呼吸困难评分等次要结局均无显著组间差异。

核心结论

  • 在慢阻肺合并慢性呼吸衰竭接受肺康复的患者中,辅助口服L-精氨酸联合脂质体维生素C与感知疲劳更大幅度的降低相关。
  • 功能结局及患者报告次要结局未见显著改善。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,共随机98例稳定期慢阻肺合并慢性呼吸衰竭且接受长期氧疗的患者。
  • 干预为在标准化28天肺康复项目期间口服L-精氨酸联合脂质体维生素C或安慰剂。
  • 主要分析采用纵向线性混合效应模型,纳入重复FSS测量、治疗组、时间、治疗×时间交互及预设协变量。

主要发现

  • FSS变化组间平均差异为-0.90(95%CI -1.50至-0.29;p=0.004)。
  • 校正治疗×时间交互分析显示校正组间差异为-0.72(95%CI -1.25至-0.20;p=0.009)。
  • 点估计超过预设最小临床重要差异0.6分。
  • 干预组FSS评分<4的比例为57%,安慰剂组为36%(p=0.059)。
  • 次要结局包括6分钟步行距离、坐立试验、握力、CAT及mMRC呼吸困难评分均无显著组间差异。

关键数值与推荐

  • 主要终点FSS组间平均差异-0.90(95%CI -1.50至-0.29;p=0.004)。
  • 校正组间差异-0.72(95%CI -1.25至-0.20;p=0.009)。
  • 预设最小临床重要差异为0.6分。
  • FSS评分<4的比例:干预组57% vs 安慰剂组36%(p=0.059)。

临床怎么用

  • 对于接受肺康复的慢阻肺合并慢性呼吸衰竭患者,可考虑辅助口服L-精氨酸联合脂质体维生素C以减轻疲劳。
  • 该干预未显示对运动功能及患者报告结局的额外获益,需结合个体情况综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive pulmonary disease (COPD), yet fatigue often persists despite rehabilitation. We conducted a multicentre, randomised, double-blind, placebo-controlled trial to evaluate whether oral L-arginine plus liposomal vitamin C improves fatigue in patients with advanced COPD and chronic respiratory failure (CRF) undergoing PR. METHODS: Consecutive patients with stable COPD and CRF receiving long-term oxygen therapy were randomised to L-arginine/liposomal vitamin C or placebo during a standardised 28-day PR programme. Fatigue was assessed using the Fatigue Severity Scale (FSS). The primary analysis used a longitudinal linear mixed-effects model including repeated FSS measurements, treatment group, time, treatment-by-time interaction and prespecified covariates. Secondary outcomes included 6 min walk distance, sit-to-stand test, handgrip strength, COPD Assessment Test and modified Medical Research Council dyspnoea score. RESULTS: 98 participants were randomised. A significant difference was found in FSS changes between groups (mean difference -0.90; 95% CI -1.50 to -0.29; p=0.004), confirmed by the adjusted treatment-by-time interaction analysis (adjusted between-group difference -0.72; 95% CI -1.25 to -0.20; p=0.009). The point estimate exceeded the prespecified minimal clinically important difference (0.6 points). A higher proportion of participants achieved an FSS score <4 in the intervention group versus placebo group (57% vs 36%; p=0.059). No significant between-group differences were observed for secondary outcomes. CONCLUSIONS: In patients with COPD and CRF undergoing PR, adjunctive oral L-arginine plus liposomal vitamin C was associated with a greater reduction in perceived fatigue, without significant improvements in functional or patient-reported secondary outcomes. TRIAL REGISTRATION NUMBER: NCT06439875.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Maniscalco M, Candia C, Fiorentino G, et al. Targeting fatigue in COPD with chronic respiratory failure undergoing pulmonary rehabilitation: a multicentre, randomised, placebo-controlled trial of L-arginine/liposomal vitamin C. Thorax. 2026. PMID: 42760127. doi:10.1136/thorax-2026-225106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。